. 2013 Aug 29;2(3):228–242. doi: 10.3390/microarrays2030228

Table 1.

Biomarkers using conventional methods and multigene classification tools for breast cancer.

Indication	IHC/FISH/RT-PCR-based tests	Ref.	Microarray-based tests	Ref.
Endrocine therapy	ESR1 * (I) (P) and PGR * (I) (P)		ESR1	[29]
			H:I ratio (tamoxifen)	[43]
			RecurrenceOnline	[40]
Targeted therapy	HER2 * (I) (F) (P)		HER2	[29]
Targeted therapy	HER2 * (I) (F) (P)		RecurrenceOnline	[40]
Grade	FoxTop (P)	[60]	MapQuant DX	[41]
Chemotherapy response	PAM50 (P)	[44]	MapQuant DX	[41]
Chemotherapy response	Oncotype DX (P)	[61]	MapQuant DX	[41]
Prognosis	Oncotype DX (P) CURIO (I) Celera Metastasis Score (P) BreastOncPx (P)	[10] [26] [56] [57]	70 gene * RecurrenceOnline IGS HDP Rotterdam signature	[42] [40] [54] [55] [62]

* FDA approved diagnostic biomarkers, (I): IHC, (F): FISH, (P): RT-PCR, ESR1: Estrogen Receptor, PGR: Progesterone Receptor, HER2: Human Epidermal Growth Factor Receptor 2.